A Validated UPLC‐MS/MS Method for Monitoring Temozolomide and Perillyl Alcohol Metabolites in Biological Matrices: Insights From a Preclinical Pharmacokinetic Study
Biomedical Chromatography · 2025
DOI: 10.1002/bmc.70253 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biomedical Chromatography, 2025. Verfasst von Ariane Krause Padilha Lorenzett und 7 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Nanostructured Formulations, Universidade Estadual do Centro-Oeste, Guarapuava, Paraná, Brazil. Hauptthemen laut MEDLINE: Tandem Mass Spectrometry, Temozolomide, Monoterpenes. Die Arbeit nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Coordenação de Aperfeiçoamento de Pessoal de Nível Superior, Conselho Nacional de Desenvolvimento Científico e Tecnológico.
Abstract (Originalsprache)
Glioblastoma multiforme (GBM) is among the most aggressive brain tumors, largely due to the restrictive blood–brain barrier (BBB) and limited drug bioavailability. Temozolomide (TMZ), an alkylating agent, and perillyl alcohol (POH), a monoterpene with antitumor properties, have shown promise in GBM therapy. This study developed and validated a UPLC‐MS/MS method for the simultaneous quantification of TMZ, its active metabolite 5‐aminoimidazole‐4‐carboxamide (AIC), and perillic acid (PA), the primary POH metabolite, in rat plasma and tissues. The method met FDA and EMA validation criteria, showing high selectivity, linearity ( R 2 > 0.995), accuracy (80%–120%), precision (RSD < 15%), and matrix‐specific stability across plasma, brain, liver, kidney, spleen, and lung. Following single oral doses of TMZ (2 mg/kg) and POH (47 mg/kg), pharmacokinetic analysis revealed that TMZ had the highest systemic exposure (AUC 0–24h : 8173.64 ng·h/mL) and C max (1448.64 ng/mL), while PA showed the fastest absorption (t max : 0.5 h). AIC levels confirmed efficient TMZ metabolism. Biodistribution analysis showed TMZ accumulation in the brain (~1000 ng/mL), supporting its CNS efficacy. PA was mainly distributed to liver and kidneys, with limited brain penetration. The validated method enables preclinical pharmacokinetic and tissue distribution studies, offering valuable insights into TMZ and POH behavior for GBM treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Laboratory of Nanostructured Formulations, Universidade Estadual do Centro-Oeste, Guarapuava, Paraná, Brazil.
- Department of Pharmacy, Universidade Estadual do Centro-Oeste, Guarapuava, Paraná, Brazil.
ORCID-Profile: Rubiana Mara Mainardes
Förderung
- Coordenação de Aperfeiçoamento de Pessoal de Nível Superior
- Conselho Nacional de Desenvolvimento Científico e Tecnológico
Zitieren
APA
Lorenzett, A. K. P., Babinski, T. P., Peczek, S. H., Tartari, A. P., Ziebarth, J., Zago, A., Pereira, T. C. B., & Mainardes, R. M. (2025). A Validated UPLC‐MS/MS Method for Monitoring Temozolomide and Perillyl Alcohol Metabolites in Biological Matrices: Insights From a Preclinical Pharmacokinetic Study. Biomedical Chromatography. https://doi.org/10.1002/bmc.70253
Vancouver
Lorenzett AKP, Babinski TP, Peczek SH, Tartari AP, Ziebarth J, Zago A, et al. A Validated UPLC‐MS/MS Method for Monitoring Temozolomide and Perillyl Alcohol Metabolites in Biological Matrices: Insights From a Preclinical Pharmacokinetic Study. Biomedical Chromatography. 2025. doi:10.1002/bmc.70253
BibTeX
@article{Lorenzett2025,
author = {Lorenzett, Ariane Krause Padilha and Babinski, Tatiane Patricia and Peczek, Samila Horst and Tartari, Ana Paula and Ziebarth, Jeferson and Zago, Andressa and Pereira, Thais Carla Brussulo and Mainardes, Rubiana Mara},
title = {A Validated UPLC‐MS/MS Method for Monitoring Temozolomide and Perillyl Alcohol Metabolites in Biological Matrices: Insights From a Preclinical Pharmacokinetic Study},
journal = {Biomedical Chromatography},
year = {2025},
doi = {10.1002/bmc.70253}
}
EUVIMED